Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | FLT1 | P17948 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | CLK2 | P49760 | 2/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.48 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.48 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | PRKCG | P05129 | 1/20 | 0.48 |
| ▸ | INSR | P06213 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | FES | P07332 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15154912 | 0.81 | SMN1; SMN2 (0.44) | DYRK1ADYRK1BMETPKMPOLB | |
| SCHEMBL23166582 | 0.81 | DYRK1A (0.39) | DYRK1AFLT3DYRK1BMETGSK3A | |
| SCHEMBL15155057 | 0.81 | JAK2 (0.48) | DYRK1AJAK2FLT1KDRAURKB | |
| SCHEMBL29954974 | 0.78 | AXL (0.39) | DYRK1ADYRK1BMETKMT2AMAPT | |
| SCHEMBL22050731 | 0.77 | JAK2 (0.41) | DYRK1AJAK2JAK3DYRK1BMET | |
| SCHEMBL7111817 | 0.76 | AXL (0.60) | DYRK1AIGF1RDYRK1BCDK8GSK3B | |
| SCHEMBL23726928 | 0.75 | DYRK1A (0.40) | DYRK1AAURKAJAK2PRKD3MAP4K4 | |
| SCHEMBL858264 | 0.75 | IDO1 (0.39) | DYRK1AAURKAJAK2PRKD3MAP4K4 | |
| SCHEMBL30376725 | 0.75 | BRAF (0.43) | DYRK1AAURKAJAK2PRKD3MAP4K4 | |
| SCHEMBL25447389 | 0.74 | BRAF (0.46) | DYRK1AAURKAJAK2PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110105356-B | Azaindole compound and preparation method and application thereof | 四川国康药业有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-109942574-B | Tianqitinib and preparation method and application thereof | 成都阿奇生物医药科技有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20210206762-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2021-07-08 | — | — | US | disclosed |
| CN-106866658-B | 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors | 沃纳利斯(R&D)有限公司 | 2021-04-27 | — | — | CN | disclosed |
| US-10889582-B2 | 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors | VERNALIS (R&D) LIMITED (GB) | 2021-01-12 | — | — | US | disclosed |
| CN-111484493-A | 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors | 沃纳利斯(R&D)有限公司 | 2020-08-04 | — | — | CN | disclosed |
| CN-109942574-A | Its surprise is for Buddhist nun and its preparation method and application | 成都阿奇生物医药科技有限公司 | 2019-06-28 | — | — | CN | disclosed |
| US-20180362526-A1 | 1H-PYRROLO [2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS DEVELOPMENT LIMITED (GB) | 2018-12-20 | — | — | US | disclosed |
| US-10000481-B2 | 1H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitors | VERNALIS (R&D) LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| EP-2809670-B1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS R&D LTD (GB) | 2017-05-17 | — | — | EP | disclosed |
| CN-104829609-B | Substituted Pyridopyrimidine compound and its preparation method and application | 北大方正集团有限公司 | 2016-08-03 | — | — | CN | disclosed |
| WO-2015120737-A1 | SUBSTITUTED PYRIDOPYRIMIDINE COMPOUNDS, PREPARATION METHODS THEREFOR AND USES THEREOF | 北大方正集团有限公司 | 2015-08-20 | — | — | WO | disclosed |
| CN-104829609-A | Substituted pyridinopyrimidine compound, preparation method and application thereof | UNIV PEKING FOUNDER GROUP CO | 2015-08-12 | — | — | CN | disclosed |
| US-20150011533-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2015-01-08 | — | — | US | disclosed |
| US-20150011533-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2015-01-08 | — | — | US | disclosed |
| EP-2809670-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Vernalis (R&D) Limited (GB) | 2014-12-10 | — | — | EP | disclosed |
| CN-104203948-A | 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors | VERNALIS R&D LTD | 2014-12-10 | — | — | CN | disclosed |
| WO-2013114113-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013114113-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2013-08-08 | — | — | WO | disclosed |
| WO-2003028724-A1 | CHK1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000481-B2 | 1H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitors | MAP4K2, MAP3K1, MAP3K19 | DYRK1A 288/4885AURKA 220/4885JAK2 39/4885 |
| US-20180362526-A1 | 1H-PYRROLO [2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | DYRK1A 288/4885AURKA 220/4885JAK2 39/4885 |
| US-20210206762-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | DYRK1A 288/4885AURKA 220/4885JAK2 39/4885 |
| US-10889582-B2 | 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors | MAP4K2, MAP3K1, MAP3K19 | DYRK1A 288/4885AURKA 220/4885JAK2 39/4885 |
| US-20150011533-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | DYRK1A 288/4885AURKA 220/4885JAK2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.